tariffs

The US administration wants to take retaliatory action for China’s rare earth export controls. US stock markets and cryptocurrencies lost billions of dollars in value on October 9, while gold has reached $4,000 an ounce. China's commerce ministry said "we aren't afraid to fight".

Bangladeshi businesses and economists are pressing the government to defer the graduation from the UN’s least developed country (LDC) status. They argue the government needs to consider the impacts on exports, tariffs, loans and patents.

Banks are looking to overhaul risk frameworks as US tariff actions collide with Asia’s export dependence. Experts shared their views on how regulators are embedding geopolitical shocks into stress scenarios, while banks turn to tech and client engagement to prepare for strains likely to surface in 2026.

The US Court of Appeals for the Federal Circuit agreed with another court's verdict that most of the tariffs are illegal; however the tariffs, including 50% on many Indian goods, will stay in place until October 14 to allow an appeal to the Supreme Court.

Hanoi’s capital market initiatives are driving Vietnamese equities higher even as concerns over Asia’s trade outlook and erratic tariffs continue to overhang sentiment.

Hong Kong stocks and listings have performed well since the start of the year as depressed valuations and budding confidence has shifted capital away from US stocks; more listings this week show the momentum is here to stay, despite tariff uncertainty.

Three judges at the US Court of International Trade have argued the Trump administration has exceeded its authority over tariffs; the judgment, which came after 12 states filed a lawsuit, has been appealed and the decision temporarily paused by another court.

Exports grew 15% in Q1, however there is expected to be a slowdown moving forward as tariffs bite, the baht remains strong and tourism faces headwinds.

Markets have rallied after a weekend agreement to reduce tariffs to 10% in China and 30% in the US is good news for companies, markets, and the US dollar; however, pharmaceutical stocks are in focus as US president Donald Trump tries to reduce drug prices.